Regeneron Pharmaceuticals (NASDAQ: REGN) revenue
Regeneron Pharmaceuticals reported revenue of $14,343m for fiscal 2025, 1.0% more than in fiscal 2024 ($14,202m). Since fiscal 2016 its revenue has grown by 195.1%, an average growth of 12.8% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $14,343m | +1.0% | $3,578m | 24.9% |
| 2024 | $14,202m | +8.3% | $3,991m | 28.1% |
| 2023 | $13,117m | +7.8% | $4,047m | 30.9% |
| 2022 | $12,173m | −24.3% | $4,739m | 38.9% |
| 2021 | $16,072m | +89.1% | $8,947m | 55.7% |
| 2020 | $8,497m | +29.6% | $3,577m | 42.1% |
| 2019 | $6,558m | +27.4% | $2,210m | 33.7% |
| 2018 | $5,146m | −12.4% | $2,534m | 49.3% |
| 2017 | $5,872m | +20.8% | $2,080m | 35.4% |
| 2016 | $4,860m | — | $1,331m | 27.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Regeneron Pharmaceuticals
- How much revenue did Regeneron Pharmaceuticals make in fiscal 2025?
- Regeneron Pharmaceuticals reported revenue of $14,343m for fiscal 2025, compared with $14,202m in fiscal 2024.
- How much has the revenue of Regeneron Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $4,860m to $14,343m: 195.1% more, an average growth of 12.8% a year.
- What was the best year for revenue at Regeneron Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2021, with $16,072m.
- Where do the figures for Regeneron Pharmaceuticals come from?
- From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Regeneron Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Regeneron Pharmaceuticals: the Regeneron Pharmaceuticals page · annual accounts · net income · dividends paid · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.